Results 111 to 120 of about 270,275 (243)

Highly loaded nanoparticulate carrier using an hydrophobic antisense oligonucleotide complex

open access: yes, 1999
Antisense oligonucleotides, and particularly those with phosphorothioate backbones, have emerged as potential gene specific therapeutic agents and are currently undergoing evaluation in clinical trials for a variety of diseases.
Stein, Cy A.   +3 more
core   +1 more source

Antisense oligonucleotides to KIF1A polymorphisms expand targets and rescue patient-derived neurons in vitro

open access: yesNature Communications
Dominant negative pathogenic variants in KIF1A result in an allelically heterogeneous neurodegenerative condition that manifests as a variable clinical phenotype including seizures, cognitive deficits, optic nerve atrophy, spasticity, and peripheral ...
Michael V. Zuccaro   +13 more
doaj   +1 more source

WO 2014203008 A1 Antisense oligonucleotide compositions

open access: yes, 2014
The present invention relates to antisense oligonucleotide (ASO) compositions and particularly to compositions and methods for the cytosolic delivery of antisense oligonucleotides (ASOs).
Mitchell, John   +2 more
core  

Exposure to an Antisense Oligonucleotide Decreases Corticotropin-Releasing Factor Receptor Binding in Rat Pituitary Cultures

open access: yes, 1995
: Corticotropin‐releasing factor (CRF) appears to integrate the endocrine, autonomic, immunologic, and behavioral responses of mammals to stress. To investigate further the role of CRF in the CNS, we have begun investigating the usefulness of “antisense ...
Owens, Michael J   +9 more
core   +1 more source

Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis

open access: yesDrug Design, Development and Therapy, 2019
Veena Mathew,1 Annabel K Wang1,2 1Department of Neurology, UCI ALS and Neuromuscular Center, University of California, Irvine, Orange, CA, USA; 2Neurology Section, Tibor Rubin VA Medical Center, Long Beach, CA, USA Abstract: Hereditary transthyretin ...
Mathew V, Wang AK
doaj  

Antisense oligonucleotide development for the treatment of muscular dystrophies

open access: yes, 2015
Introduction: Depending upon the chemistry and annealing target, antisense oligonucleotides can be used to modify gene expression through several distinct modes of action.
Bao, T.L.   +3 more
core  

Bioconjugation strategies for oligonucleotide functionalisation

open access: yes
Chemical modification of oligonucleotides has gained growing attention in research and therapeutic areas as these modalities, such as ribose modifications or fluorescent tags, have shown great promise to improve therapeutic properties and enable real ...
Chik, Gerald
core   +1 more source

Evaluating the Specificity of Antisense Oligonucleotide Conjugates: A DNA ARRAY ANALYSIS

open access: yes, 2002
Antisense oligonucleotides are potentially powerful tools for selective control of cellular and viral gene expression. Crucial to successful application of this approach is the specificity of the oligonucleotide for the chosen RNA target.
Fisher, Michael H.   +5 more
core   +1 more source

Imaging-Assisted Antisense Oligonucleotide Delivery for Tumor-Targeted Gene Therapy

open access: yes
Antisense oligonucleotide (ASO) represents a class of practical tools for targeting undruggable oncogenes with several candidates currently undergoing clinical investigation. The advancement of antisense therapeutics necessitates comprehensive approaches
Hanwen Liao (18396321)   +6 more
core   +1 more source

Inhibition of pteridine reductase 1 (PTR1) expression in Leishmania promastigotes using a full-length antisense construct

open access: yes, 2009
Leishmania exhibit many unusual features, one of which is the pteridine metabolic pathway essential for the growth for these parasites. Leishmania have evolved a complex and versatile pteridine salvage network capable of scavenging a wide array of ...
Nariman Mosaffa   +7 more
core  

Home - About - Disclaimer - Privacy